Advertisement

De novo malignancies following renal transplantation

  • Norio Yoshimura
  • Takahiro Oka
Part of the Transplantation and Clinical Immunology book series (TRAC, volume 27)

Abstract

As renal transplantation is being increasingly undertaken for growing numbers of patients with end-stage renal disease, there has been a trend toward offering this treatment to patients who have undergone successful treatment for malignant disease. Malignancies following immunosuppressive therapy have been observed at all transplantation centers and much material has been published on this subject in recent years [1–8].

Keywords

Graft Survival Renal Transplant Recipient Transplant Proc Kidney Transplant Recipient Graft Survival Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Penn I. Cancers of the anogenical region in renal transplant recipients. Analysis of 65 cases. Cancer 1986; 58: 611–616.PubMedCrossRefGoogle Scholar
  2. 2.
    Penn I. Why do immunosuppressed patients develop cancer?, in Pimentel E (ed): CRC Critical reviews in oncogenesis. Boca Raton, FL, CRC, 1989; 27–52.Google Scholar
  3. 3.
    Penn I. Post-transplant kidney cancers and skin cancers (including Kaposi’s sarcoma), in Schmahl D, Penn I (eds): Cancer in organ transplant recipients. New York, NY, Springer-Verlag, 1991; 46–53.Google Scholar
  4. 4.
    Penn I. Immunosuppression-A contributory factor in lymphoma formation. Clin Transplant 1992; 6:214–219.Google Scholar
  5. 5.
    Penn I. Immunosuppression and opportunistic tumors: Do viruses play a role?, in Dammacco F (ed): Advances in tumor immunology and allergic disorders. Immuno Incontri, Milan, Italy, Edi Ermes, 1992; 139–162.Google Scholar
  6. 6.
    Sheil AJR. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc, 1993; 25:1383.PubMedGoogle Scholar
  7. 7.
    Frei U, Bode U, Repp H et al. Malignancies under cyclosporine after kidney transplantation: Analysis of a 10-year period. Transplant Proc, 1993; 25:1394.PubMedGoogle Scholar
  8. 8.
    Shel AJR. Development of malignancy following renal Transplantation in Australia and New Zealand. Transplant Proc, 1992; 24: 1275.Google Scholar
  9. 9.
    Oka T, Ohmori Y, Aikawa I et al. Early conversion of CsA to Az in living related renal transplantation. Transplant Proc, 1989; 21: 1645–1648.Google Scholar
  10. 10.
    Tokoro Y, Asano T, Nakagouri T et al. A Statistical Study of Cancer Incidence in Renal Transplant Patients. Transplant Proc, 1992; 24: 1588–1590.PubMedGoogle Scholar
  11. 11.
    Sheil AGR, Disney APS, Mathew TH et al. Cancer development in cadaveric donor renal allograft recipients treated with azathioprine (AZA) or cyclosporine (CyA) or AZA/CyA. Transplant Proc, 1991; 23: 1111–1112.PubMedGoogle Scholar
  12. 12.
    Gruber SA, Skjei KL, Sothern RB et al. Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression. Transplant Proc, 1991; 23: 1104–1105.PubMedGoogle Scholar
  13. 13.
    Swinnen LJ, Constanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723–1728.PubMedCrossRefGoogle Scholar
  14. 14.
    Cockfield SM, Preiksaints J, Harvey E et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991; 23: 1106–1107.PubMedGoogle Scholar
  15. 15.
    Fukuda M, Aikawa I, Ohmori Y et al. Chromosome aberration in kidney transplant recipients. Transplant Proc 1987; 19: 2245–2247.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Norio Yoshimura
  • Takahiro Oka

There are no affiliations available

Personalised recommendations